Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report)'s share price passed below its 200-day moving average during trading on Wednesday following insider selling activity. The stock has a 200-day moving average of $160.40 and traded as low as $158.34. Revolution Medicines shares last traded at $159.82, with a volume of 2,339,794 shares.
Specifically, insider Stephen Kelsey sold 27,160 shares of the stock in a transaction on Monday, November 16th. The shares were sold at an average price of $167.86, for a total value of $4,559,077.60. Following the sale, the insider directly owned 286,307 shares in the company, valued at approximately $48,059,493.02. This trade represents a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Jack Anders sold 35,750 shares of Revolution Medicines stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $188.10, for a total transaction of $6,724,575.00. Following the transaction, the chief financial officer directly owned 119,216 shares in the company, valued at approximately $22,424,529.60. This represents a 23.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information.
Analyst Upgrades and Downgrades
A number of research firms recently commented on RVMD. Bank of America lowered their price objective on shares of Revolution Medicines from $265.00 to $264.00 and set a "buy" rating for the company in a research report on Friday, October 9th. UBS Group lifted their target price on Revolution Medicines from $220.00 to $265.00 and gave the stock a "buy" rating in a report on Friday, August 28th. Needham & Company LLC reissued a "buy" rating and issued a $275.00 target price on shares of Revolution Medicines in a research note on Thursday, October 15th. Piper Sandler boosted their target price on Revolution Medicines from $210.00 to $222.00 and gave the company an "overweight" rating in a research note on Thursday, November 5th. Finally, Raymond James Financial restated a "strong-buy" rating and issued a $248.00 price target on shares of Revolution Medicines in a report on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $262.75.
Get Our Latest Stock Report on Revolution Medicines
Revolution Medicines Stock Performance
The stock has a market cap of $34.57 billion, a P/E ratio of -17.54 and a beta of 1.44. The company has a debt-to-equity ratio of 0.44, a current ratio of 8.36 and a quick ratio of 8.34. The stock's 50 day simple moving average is $191.75 and its two-hundred day simple moving average is $160.40.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.35) by $0.45. The company had revenue of $197.56 million for the quarter, compared to the consensus estimate of $25.58 million. During the same period in the prior year, the company earned ($1.61) EPS. As a group, research analysts forecast that Revolution Medicines, Inc. will post -7.41 EPS for the current year.
Hedge Funds Weigh In On Revolution Medicines
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Burkett Financial Services LLC acquired a new stake in shares of Revolution Medicines in the 3rd quarter valued at about $27,000. Contravisory Investment Management Inc. acquired a new position in shares of Revolution Medicines during the second quarter worth about $32,000. ABS Investment Management LLC acquired a new position in shares of Revolution Medicines during the second quarter worth about $337,104,000. Johnson Financial Group Inc. acquired a new position in shares of Revolution Medicines during the second quarter worth about $37,000. Finally, Mather Group LLC. bought a new position in shares of Revolution Medicines during the third quarter worth about $41,000. 94.34% of the stock is owned by institutional investors and hedge funds.
About Revolution Medicines
(
Get Free Report)
Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company's research centers on RAS proteins, which can contribute to the growth of many cancers. The company's pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Revolution Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revolution Medicines wasn't on the list.
While Revolution Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.